Sumitomo Pharma announces availability of ORGOVYX in Canada

The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer

Govt. announces the revamped pharmaceuticals technology upgradation assistance scheme

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Adani and Sirius form JV to digitally transform India's digital economy

Sirius JV will be owned 51% by Sirius and 49% by Adani

Lupin Atlantis Holdings to acquire accretive established products in Europe and Canada from Sanofi

The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired

Biocon Biologics signs distribution partnership with Sandoz for Adalimumab BS Subcutaneous Injection in Japan

The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio

Sulzer launches new biodegradable polymer

The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates

Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer

Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada

Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada

Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market

Sun Pharma Canada launches Prwinlevi for treatment for acne

WINLEVI works differently from any other topical acne treatment